Saturday 17 October 2026
Export SNOA’s income statement to Excel — free account
Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
1.13
0.02
−1.74%
Follow SNOA
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 4 | 5 | 2 | 3 | 2 | 4 | 3 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.26 |
P/S ratio |
0.18 | 0.19 | 0.11 | 0.25 | 0.84 | 0.80 | 0.40 | 0.40 | 1.02 | 2.36 |
Altman Z-Score |
(18.52) | (19.15) | (17.82) | (15.47) | (12.75) | (14.63) | (16.19) | (15.73) | (9.65) | (3.62) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(44.40) | (44.32) | (40.45) | (34.87) | (29.40) | (36.06) | (38.60) | (36.60) | (23.10) | (11.17) |
P/Operating CF |
(6.91) | (28.61) | 8.98 | (1.36) | (7.63) | (10.05) | (2.02) | (2.79) | (5.57) | (11.25) |
Beneish M-Score |
(1.69) | (4.09) | (3.22) | (1.93) | (2.70) | (2.98) | (1.88) | (1.67) | (2.99) | 2.72 |
P/B ratio |
1.16 | 0.62 | 0.22 | 0.42 | 1.22 | 2.77 | 1.29 | 0.73 | 1.11 | 1.42 |
Price to Tangible BV |
1.16 | 0.62 | 0.22 | 0.42 | 1.22 | 2.77 | 1.29 | 0.73 | 1.11 | 1.42 |
EV/Sales |
0.07 | (0.18) | (0.11) | 0.00 | 0.35 | 0.67 | 0.27 | 0.23 | 0.44 | 1.03 |
EV/EBITDA |
0.00 | 0.72 | 0.31 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.33) | 29.08 | 0.59 | 0.01 | (1.03) | (3.71) | (1.04) | (0.37) | (0.59) | (1.62) |
EV/FCF |
(0.31) | 15.23 | 0.59 | 0.01 | (1.00) | (3.52) | (1.00) | (0.36) | (0.58) | (1.54) |
Quick Ratio |
1.02 | 1.86 | 1.62 | 1.72 | 1.68 | 1.72 | 1.62 | 2.00 | 3.56 | 5.95 |
Current Ratio |
2.50 | 3.09 | 3.37 | 3.71 | 2.82 | 3.18 | 2.60 | 3.48 | 4.98 | 6.89 |
Net Debt/EBITDA |
1.03 | 1.50 | 0.62 | 0.76 | 1.16 | 0.72 | 0.42 | 0.31 | 0.71 | 1.35 |
Debt/Assets |
0.00% | 0.00% | 2.19% | 2.66% | 4.29% | 12.72% | 4.92% | 2.31% | 2.11% | 1.32% |
Debt/Equity |
0.00 | 0.00 | 0.05 | 0.05 | 0.09 | 0.36 | 0.13 | 0.03 | 0.03 | 0.02 |
Asset Turnover |
1.41 | 1.01 | 0.82 | 0.76 | 0.75 | 1.26 | 1.24 | 1.13 | 0.75 | 0.65 |
Operating CF/Net income |
1.24 | 0.03 | 0.50 | 1.19 | 0.84 | 0.86 | 1.39 | 0.99 | 0.87 | (0.88) |
Capex/Depreciation |
(1.38) | (0.58) | (0.01) | (2.15) | (0.74) | (0.79) | (0.66) | (0.22) | (0.38) | (1.59) |
Interest Coverage |
— | — | — | (285.62) | — | (215.56) | (461.87) | (341.15) | (354.72) | (4,324.67) |
| (84.60%) | (65.55%) | (68.51%) | (61.78%) | (72.35%) | (71.90%) | (41.06%) | (91.40%) | (77.96%) | 58.75% | |
| (22.96%) | (24.32%) | (31.22%) | (29.37%) | (30.07%) | (26.74%) | (22.81%) | (70.11%) | (64.16%) | 47.24% | |
ROIC |
(220.99%) | 0.00% | (88.18%) | (62.25%) | (174.46%) | (70.70%) | (174.36%) | (98.63%) | (156.51%) | (188.31%) |
Return on Tangible Assets |
(41.90%) | (39.39%) | (52.59%) | (48.74%) | (46.53%) | (42.63%) | (41.77%) | (122.49%) | (101.41%) | 45.03% |
Average Days of Receivables |
47.23 | 57.02 | 83.06 | 70.73 | 69.57 | 54.98 | 80.89 | 66.98 | 33.68 | 59.99 |
Research and Development Expense of Revenue |
11.63% | 12.70% | 14.69% | 1.56% | 0.99% | 2.98% | 7.47% | 8.00% | 9.45% | 12.29% |
Selling, General and Administrative Expense of Revenue |
38.94% | 51.52% | 59.48% | 66.61% | 77.25% | 50.74% | 79.06% | 98.15% | 119.61% | 133.07% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.31% | 1.57% | 4.05% | 5.04% | 3.03% | 1.99% | 4.68% | 8.62% | 15.01% | 17.49% |
Graham Net Nets |
0.34 | 1.24 | 2.89 | 1.67 | 0.59 | 0.23 | 0.46 | 1.12 | 0.73 | 0.61 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,850.68 |
Earnings Yield |
(88.73%) | (141.55%) | (486.67%) | (158.16%) | (45.39%) | (19.92%) | (45.65%) | (165.47%) | (84.23%) | 30.69% |
Free Cash Flow Yield |
(115.00%) | (6.18%) | (175.82%) | (193.05%) | (41.20%) | (23.98%) | (66.24%) | (154.46%) | (74.43%) | (28.23%) |
Revenue per Share |
11.60 | 11.51 | 27.99 | 78.21 | 95.16 | 186.66 | 242.60 | 410.61 | 661.03 | 545.74 |
Operating CF per Share |
(2.34) | (0.07) | (5.27) | (36.25) | (32.01) | (33.85) | (62.12) | (253.61) | (493.61) | (347.53) |
Capex per Share |
(0.11) | (0.06) | 0.00 | (1.59) | (1.03) | (1.79) | (2.79) | (2.16) | (7.42) | (16.77) |
Free Cash Flow per Share |
(2.45) | (0.14) | (5.27) | (37.84) | (33.04) | (35.64) | (64.91) | (255.78) | (501.03) | (364.30) |
Cash per Share |
1.42 | 4.33 | 6.87 | 22.51 | 55.73 | 42.28 | 49.95 | 79.85 | 399.44 | 743.02 |
Shareholders Equity per Share |
1.84 | 3.55 | 13.49 | 47.01 | 65.54 | 53.74 | 76.10 | 227.03 | 608.17 | 911.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.84 | 3.55 | 13.49 | 47.01 | 65.54 | 53.74 | 76.10 | 227.03 | 608.17 | 911.96 |
Free Cash Flow |
(4.12) | (0.17) | (2.40) | (6.42) | (4.38) | (3.56) | (4.80) | (11.82) | (12.63) | (8.56) |
Working Capital |
7.27 | 8.55 | 8.83 | 10.08 | 10.61 | 8.91 | 7.55 | 8.91 | 12.99 | 19.36 |
Capital Expenditures |
(0.19) | (0.08) | 0.00 | (0.27) | (0.14) | (0.18) | (0.21) | (0.10) | (0.19) | (0.39) |
Net Current Asset Value |
1.24 | 3.37 | 3.95 | 5.54 | 6.28 | 3.36 | 3.35 | 8.54 | 12.37 | 18.62 |
EV/EBIT |
0.00 | 0.69 | 0.30 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.45 | 0.61 | 0.48 | 0.26 | 0.58 | 0.63 | 0.85 | 0.62 | 0.43 | 0.20 |
Cash ROIC |
(75.08%) | (1.72%) | (25.03%) | (52.51%) | (25.95%) | (30.96%) | (47.82%) | (81.43%) | (48.94%) | (21.82%) |
Accounts Receivable Turnover |
8.21 | 5.57 | 4.66 | 5.33 | 4.84 | 5.50 | 4.81 | 7.56 | 9.14 | 7.09 |
Accounts Payable Turnover |
8.42 | 11.31 | 11.04 | 7.09 | 5.06 | 6.29 | 5.90 | 7.99 | 7.40 | 5.52 |
Inventory Turnover |
3.69 | 3.13 | 2.87 | 3.19 | 3.33 | 5.12 | 3.51 | 3.22 | 3.68 | 3.75 |
Average Days of Payables |
57.94 | 39.42 | 27.73 | 34.90 | 69.36 | 53.50 | 76.94 | 45.40 | 49.67 | 64.00 |
Days of Inventory on Hand |
110.01 | 120.59 | 124.21 | 118.61 | 112.56 | 76.51 | 81.18 | 123.32 | 111.87 | 113.27 |
Average Receivables |
2.38 | 2.57 | 2.74 | 2.49 | 2.61 | 3.39 | 3.73 | 2.51 | 1.82 | 1.81 |
Average Payables |
1.44 | 0.78 | 0.72 | 1.24 | 1.71 | 1.92 | 1.66 | 1.26 | 1.26 | 1.30 |
Average Inventory |
3.28 | 2.82 | 2.79 | 2.76 | 2.60 | 2.36 | 2.80 | 3.14 | 2.54 | 1.91 |
Average Assets |
13.83 | 14.22 | 15.49 | 17.54 | 16.92 | 14.77 | 14.50 | 16.83 | 22.33 | 19.63 |
Average Common Equity |
3.75 | 5.27 | 7.06 | 8.34 | 7.03 | 5.49 | 8.06 | 12.91 | 18.38 | 15.79 |
Columns are period end dates